Association of AGTR1 and ACACB Gene Polymorphism and Diabetic Nephropathy in Type 2 Diabetes
This study has been completed.
Information provided by (Responsible Party):
Anil Bhansali, Postgraduate Institute of Medical Education and Research
First received: February 16, 2010
Last updated: October 23, 2015
Last verified: October 2015
India is the "Diabetes Capital of the World" with 41 million Indians having diabetes, with every fifth diabetic in the world being an Indian and type 2 Diabetes Mellitus (T2DM) constitutes the major chunk of diabetes. One of the most severe complications of diabetes is the development of diabetic nephropathy. Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide. There are many identifiable risk factors of diabetic nephropathy like hyperglycemia, hyperlipidemia, hypertension, and proteinuria, the genetic factor is the main among all. Long-term observational studies show that nearly 30-35% of type 2 diabetic patients develop nephropathy, irrespective of glycemic control. The regional variation in diabetes prevalence and in the proclivity for diabetes induced renal disease; along with reports of familial clustering of nephropathy suggest a possible genetic basis. The renin-angiotensin system (RAS) has been strongly implicated in the pathogenesis of progressive renal diseases. In addition, the blockage of angiotensin II with either ACE inhibitor or an angiotensin type-I receptor antagonist has been found to prevent or delay the progression of renal injury associated with diabetes 5 and now these drugs are first-choice drugs for the treatment of diabetic subjects with hypertension. The genes encoding the renin-angiotensin system (RAS), such as angiotensin-converting enzyme (ACE), angiotensinogen (AGT) and angiotensin II receptor type 1 (AGTR1), have been reported to be the most probable candidate genes for diabetic nephropathy. As there is no data available for AGTR1 polymorphism and DN in the north Indian T2DM, its out attempt to fill the scientific gap.
Diabetes Mellitus, Type 2
||Observational Model: Case Control
Time Perspective: Cross-Sectional
||Study of the Association of AGTR1 and ACACB Gene Polymorphism and Susceptibility of Diabetic Nephropathy in North Indian Type 2 Diabetic Patients
Biospecimen Retention: Samples With DNA
4 ml of whole blood sample.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2011 (Final data collection date for primary outcome measure)
subjects with diabetic nephropathy.
Subjects with Type 2 Diabetes. Duration of diabetes should be more than or equal to 5 years. Age between 30 and 85 years. Diabetic nephropathy as defined by ADA.
Subject must be of north Indian origin.
Type 1 diabetes and kidney disease other than diabetes nephropathy are excluded form the study.
Subjects without Diabetic nephropathy.
This group of subject with similar characteristics as group 1 without any evidence of nephropathy.
|Ages Eligible for Study:
||30 Years to 85 Years (Adult, Senior)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
Study Population for Group 1 and Group-2 (Subjects with diabetic nephropathy and without nephropathy respectively)will be recruited from the diabetic Out Patient and in patient services of Postgraduate Institute of Medical Education & Research and Nehru hospital, Chandigarh. Only North Indian Ethnic subjects will be recruited.
Group:-1: Patients with diabetic nephropathy
- Type 2 Diabetes and duration of more than or equal to 5 years.
- Age between 30 to 85 years.
- Presence of both albuminuria and retinopathy.
- Patients with diagnosis of type 1 diabetes
- Any known nondiabetic renal disease.
- Patients who had a MI or had undergone CABG within 3 month.
- Patients who had a CVA or had undergone PTCA in the previous 3 months.
- Patients who had had a transient ischemic attack within the previous 3 months.
- Patients who had any history of heart failure before enrollment.
- Patients with UTI.
- Pregnant patient.
Group:-2: Patients without diabetic nephropathy Same characteristic as group 1 but no evidence of diabetic nephropathy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01069549
|Postgraduate Institute of Medical Education & Research
|Chandigarh, India, 1610012 |
Postgraduate Institute of Medical Education and Research
||anil Bhansali, DM
||Postgradute Institute of Medical Education & Research
||Anil Bhansali, prof and head, Postgraduate Institute of Medical Education and Research
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 16, 2010
||October 23, 2015
Keywords provided by Postgraduate Institute of Medical Education and Research:
Type 2 Diabetes Mellitus
Angiotensin II type 1 receptor gene polymorphism
Acetyl coA carboxylase beta gene polymorphism.
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 24, 2017
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Endocrine System Diseases